Intuitive Surgical, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; comparisons are with Q1 2023 unless noted. Intuitive develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system, along with related instruments, accessories, and services. Amounts below are in U.S. dollars.
Financial and operating performance
| Metric | Q1 2024 | Q1 2023 | Change / context |
|---|---|---|---|
| Total revenue | $1.891 billion | $1.696 billion | Up 11% |
| Instruments and accessories revenue | $1.159 billion | $985.6 million | Up 18%; driven primarily by procedure growth and higher pricing |
| Systems revenue | $418.2 million | $427.4 million | Down 2%; more placements under operating leases and lower average selling price |
| Service revenue | $313.5 million | $283.2 million | Up 11% |
| Gross profit / gross margin | $1.245 billion / 65.9% | $1.113 billion / 65.6% | Margin up 0.3 percentage points |
| Operating income / margin | $469.4 million / 24.8% | $387.6 million / 22.9% | Operating income up 21% |
| Net income attributable to Intuitive | $544.9 million | $355.3 million | Up 53%; includes a material income tax benefit |
| Diluted EPS | $1.51 | $1.00 | Up 51% |
| Operating cash flow | $265.4 million | $371.4 million | Down 29% |
| Capital expenditures | $241.9 million | $194.1 million | Higher investment in facilities and capacity |
Product gross margin declined to 64.8% from 65.1%, mainly due to higher inventory reserves and fixed overhead, including manufacturing-capacity depreciation and share-based compensation. Service gross margin improved to 71.0% from 68.1%, supported by repair-volume efficiencies. R&D expense rose 16% to $284.5 million; SG&A increased 2% to $491.5 million.
Revenue from the U.S. was $1.239 billion (66% of total); outside the U.S. (OUS) revenue was $652.1 million. Foreign currency movements, net of hedging, reduced OUS revenue by approximately $11 million.
Cash, liquidity, and capital
Cash, cash equivalents, and short- and long-term investments totaled $7.32 billion at March 31, 2024, versus $7.34 billion at year-end 2023. Current assets were $7.63 billion and current liabilities $1.38 billion. The balance sheet reports no debt line item. Total liabilities were $1.78 billion and stockholders’ equity was $14.05 billion.
Operating cash flow was below net income, principally reflecting working-capital outflows: accrued compensation and benefits fell by $271 million, mainly due to payment of 2023 incentives; inventory used $180 million of cash, including equipment transferred to property and equipment; and other liabilities used $76 million, primarily due to tax payments. Financing cash outflow was $46.7 million, including $226.6 million in taxes paid on net share settlements of equity awards, partly offset by $180.4 million of employee-plan stock proceeds. No shares were repurchased in the quarter; approximately $1.1 billion remained authorized.
Business trends, outlook, risks, and unusual items
- Da Vinci procedures grew approximately 16% to 627,000, versus 26% growth in Q1 2023; U.S. procedures grew 14% and OUS procedures 20%. Management attributes part of the prior-year comparison to COVID-related treatment backlogs. Ion procedures grew 90% to approximately 19,500.
- Da Vinci placements were 313, versus 312 a year earlier; installed base reached approximately 8,887, up 14%. Ion placements were 70, and its installed base reached approximately 604, up 61%. Da Vinci utilization per system increased 2% year over year.
- Recurring revenue, as defined by the company, was $1.620 billion, or 86% of revenue, compared with $1.381 billion, or 81%. Operating lease revenue was $148 million, including $70 million of usage-based variable revenue.
- Da Vinci 5 received FDA clearance in March 2024, with eight systems installed at quarter-end. Management plans a phased launch over several quarters to mature manufacturing and supply processes. The da Vinci SP installed base was 201; management plans a measured European rollout during 2024. Ion received Chinese regulatory clearance in March, with a measured launch planned later in 2024.
- Management expects 2024 capital expenditures of $1.0–$1.2 billion, primarily for facilities, funded from operating cash. It expects substantial R&D investment to continue increasing. The filing does not provide specific full-year revenue, procedure-growth, or earnings guidance.
- Management says supply constraints have eased but remain for certain engineered materials and components; elevated input costs, supplier concentration, labor availability, and hospital staffing and financial pressures could affect deliveries, procedures, and system placements. Higher interest rates, inflation, geopolitical conflicts, tariffs, and competition may add pressure. Hospital capital spending and Chinese system tenders remain uncertain; the Chinese government’s governance campaign contributed to fewer placements there in Q1.
- The effective tax rate was negative 1.7%, versus 14.5% a year earlier, primarily reflecting $111.1 million of excess tax benefits from employee equity plans (reducing the rate by 20.6 percentage points) and higher R&D credits. This benefit is variable and makes earnings and tax rates less comparable across periods.
- Material litigation includes da Vinci product-liability claims and antitrust cases concerning instrument servicing and repair. In March 2024, courts allowed parts of the antitrust claims to proceed; Intuitive disputes the allegations. The company cannot reasonably estimate potential losses beyond recognized amounts for the identified matters. Several product-liability cases have trial dates in the next 12 months.
Most important facts for investors to verify
- Whether da Vinci and Ion procedure growth, utilization, and recurring revenue sustain momentum as prior-year COVID-backlog effects diminish.
- How operating-lease mix, system pricing, trade-ins, and geographic mix affect systems revenue and average selling prices.
- Whether the Da Vinci 5, SP, and Ion launches meet rollout, regulatory, manufacturing, and customer-adoption milestones.
- Whether operating cash flow recovers from working-capital demands while planned 2024 capital spending rises to $1.0–$1.2 billion.
- Developments in Chinese tenders and pricing or reimbursement restrictions, supply-chain and hospital-spending risks, and the pending litigation exposure.
- The sustainability of reported earnings growth given the unusually favorable, equity-award-related tax benefit.